Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. (Q43755014)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

0 references

1 reference

V A Fonseca

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

W Wilpshaar

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

P Dhanjal

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

A Houzer

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

7 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

403-409

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

Renal glucose reabsorption inhibitors to treat diabetes

18 February 2020

cites work

1 reference

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

21 January 2018

1 reference

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

21 January 2018

1 reference

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus

21 January 2018

1 reference

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

EuroQol: the current state of play

21 January 2018

1 reference

Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience.

21 January 2018

1 reference

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years

21 January 2018

1 reference

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163880%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference